Infinity Pharmaceuticals, Inc.

Equities

INFI.Q

US45665G3039

Biotechnology & Medical Research

End-of-day quote OTC Markets Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
0.000001 ^USD	0.00%		0.00%	-99.96%

Mar. 25	North American Morning Briefing : Tech in Focus on -2-	DJ
Mar. 25	Infinity Pharmaceuticals, Inc. Went Out of Business	CI

Infinity Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2021

July 27, 2021 at 07:30 am EDT

Infinity Pharmaceuticals, Inc. announced earnings results for the second quarter ended June 30, 2021. For the second quarter, the company announced operating loss was USD 11.251 million compared to USD 8.919 million a year ago. Net loss was USD 11.269 million compared to USD 9.473 million a year ago. Basic loss per share from continuing operations was USD 0.13 compared to USD 0.16 a year ago. For the half year, operating loss was USD 22.833 million compared to USD 19.418 million a year ago. Net loss was USD 22.898 million compared to USD 20.359 million a year ago. Basic loss per share from continuing operations was USD 0.28 compared to USD 0.35 a year ago.

Latest news about Infinity Pharmaceuticals, Inc.

North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Infinity Pharmaceuticals, Inc. Went Out of Business	Mar. 25	CI
Revised Liquidation Plan Approved for Infinity Pharmaceuticals, Inc.	Mar. 06	CI
Motion for Di Minimis Assets Sale Approved for Infinity Pharmaceuticals, Inc.	Feb. 21	CI
An unknown healthcare investment firm acquired Substantially all of the assets of Infinity Pharmaceuticals, Inc. (OTCPK:INFI.Q).	Feb. 14	CI
First Motion for Exclusivity Period Extension Approved For Infinity Pharmaceuticals, Inc.	Feb. 12	CI
Disclosure Statement Approved on Interim Basis for Infinity Pharmaceuticals, Inc.	Feb. 01	CI
First Motion for Exclusivity Period Extension Filed by Infinity Pharmaceuticals, Inc.	Jan. 25	CI
North American Morning Briefing : Tech Likely to -2-	Jan. 19	DJ
North American Morning Briefing : Stock Futures Waver Ahead of Bank-Earnings Bonanza	Jan. 12	DJ
Joint Liquidation Plan and Disclsoure Statement Filed by Infinity Pharmaceuticals, Inc.	Jan. 10	CI
Motion for Asset Sale Approved for Infinity Pharmaceuticals, Inc.	Jan. 07	CI
North American Morning Briefing : Bond Yields Rise -2-	Jan. 05	DJ
North American Morning Briefing : Stock Futures Gain as 2023 Draws to a Close	Dec. 29	DJ
North American Morning Briefing : Stock Futures -2-	Dec. 18	DJ
North American Morning Briefing : Investors Await -2-	Dec. 11	DJ
North American Morning Briefing : Stock Futures, -2-	Dec. 04	DJ
North American Morning Briefing : Stock Futures -2-	Nov. 27	DJ
North American Morning Briefing : Stocks Futures Steady on Rates Optimism	Nov. 20	DJ
North American Morning Briefing : Stock Futures -2-	Nov. 13	DJ
Bidding Procedure Approved for Infinity Pharmaceuticals, Inc.	23-10-23	CI
Motion for Joint Administration Approved for Infinity Pharmaceuticals, Inc.	23-10-02	CI
Infinity Pharmaceuticals, Inc. Announces Resignation of Adelene Perkins from the Board	23-09-29	CI
INFINITY PHARMACEUTICALS LISTS BOTH ESTIMATED ASSETS AND LIABILI…	23-09-29	RE
Motion for Asset Sale Filed by Infinity Pharmaceuticals, Inc.	23-09-29	CI

Chart Infinity Pharmaceuticals, Inc.

Duration

Period

More charts

Company Profile

Infinity Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company that is focused on developing medicines for people with cancer. The Company is focused on advancing eganelisib, also known as IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that reprograms macrophages through selective inhibition of the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma). Its eganelisib clinical development program includes MAcrophage Reprogramming in Immuno-Oncology-3 (MARIO-3), MARIO-275 and MARIO-1. MARIO-3 is a multi-arm Phase II study designed to evaluate eganelisib in the front-line treatment for both metastatic triple-negative breast cancer (TNBC), and renal cell carcinoma (RCC). MARIO-275 is its global, randomized, placebo-controlled Phase II study evaluating the effect of adding eganelisib to nivolumab, also known as Opdivo, in checkpoint-naive advanced urothelial cancer (UC). MARIO-1 is in the Phase I/Ib clinical study.

Sector

Biotechnology & Medical Research

More about the company

	1st Jan change	Capi.
INFINITY PHARMACEUTICALS, INC.	-99.96%	90
IQVIA HOLDINGS INC.	+1.51%	42.59B
MODERNA, INC.	+8.57%	40.65B
LONZA GROUP AG	+49.22%	40.57B
CELLTRION, INC.	-12.36%	26.77B
ICON PUBLIC LIMITED COMPANY	+8.92%	24.81B
ALNYLAM PHARMACEUTICALS, INC.	-25.13%	18.17B
MEDPACE HOLDINGS, INC.	+29.17%	12.05B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.12%	11.7B
UNITED THERAPEUTICS CORPORATION	+6.35%	11.1B

Other Biotechnology & Medical Research